CN1234367C - 用于压迫性尿失禁治疗的芳基偶氮－取代的咪唑 - Google Patents

用于压迫性尿失禁治疗的芳基偶氮－取代的咪唑 Download PDF

Info

Publication number
CN1234367C
CN1234367C CNB028129687A CN02812968A CN1234367C CN 1234367 C CN1234367 C CN 1234367C CN B028129687 A CNB028129687 A CN B028129687A CN 02812968 A CN02812968 A CN 02812968A CN 1234367 C CN1234367 C CN 1234367C
Authority
CN
China
Prior art keywords
imidazole
azo
chloro
arylazo
urinary incontinence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028129687A
Other languages
English (en)
Chinese (zh)
Other versions
CN1541099A (zh
Inventor
R·W·格里斯特伍德
D·卡瓦拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Su Ci Co Ltd
Arachnova Therapeutics Ltd
Original Assignee
Su Ci Co Ltd
Arachnova Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Su Ci Co Ltd, Arachnova Therapeutics Ltd filed Critical Su Ci Co Ltd
Publication of CN1541099A publication Critical patent/CN1541099A/zh
Application granted granted Critical
Publication of CN1234367C publication Critical patent/CN1234367C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB028129687A 2001-06-08 2002-06-07 用于压迫性尿失禁治疗的芳基偶氮－取代的咪唑 Expired - Fee Related CN1234367C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0114008.6 2001-06-08
GBGB0114008.6A GB0114008D0 (en) 2001-06-08 2001-06-08 New therapautic use

Publications (2)

Publication Number Publication Date
CN1541099A CN1541099A (zh) 2004-10-27
CN1234367C true CN1234367C (zh) 2006-01-04

Family

ID=9916211

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028129687A Expired - Fee Related CN1234367C (zh) 2001-06-08 2002-06-07 用于压迫性尿失禁治疗的芳基偶氮－取代的咪唑

Country Status (13)

Country Link
US (1) US20040242547A1 (https=)
EP (1) EP1399167A1 (https=)
JP (1) JP2005500285A (https=)
KR (1) KR20040030654A (https=)
CN (1) CN1234367C (https=)
AU (1) AU2002311445B2 (https=)
BR (1) BR0210195A (https=)
CA (1) CA2449957A1 (https=)
GB (1) GB0114008D0 (https=)
MX (1) MXPA03011226A (https=)
RU (1) RU2004100228A (https=)
WO (1) WO2002100414A1 (https=)
ZA (1) ZA200309473B (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056123B2 (ja) * 1979-07-30 1985-12-09 持田製薬株式会社 浮腫・低血圧・心不全および粘膜充血治療用剤
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
US6323231B1 (en) * 2000-02-17 2001-11-27 Abbott Laboratories Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence

Also Published As

Publication number Publication date
MXPA03011226A (es) 2004-03-26
CN1541099A (zh) 2004-10-27
US20040242547A1 (en) 2004-12-02
KR20040030654A (ko) 2004-04-09
GB0114008D0 (en) 2001-08-01
ZA200309473B (en) 2005-03-23
AU2002311445B2 (en) 2005-08-25
BR0210195A (pt) 2004-07-27
JP2005500285A (ja) 2005-01-06
RU2004100228A (ru) 2005-06-10
EP1399167A1 (en) 2004-03-24
WO2002100414A1 (en) 2002-12-19
CA2449957A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
Moravec et al. Inotropic effects of angiotensin II on human cardiac muscle in vitro.
Schiffrin et al. Structure and function of resistance arteries of hypertensive patients treated with a p-blocker or a calcium channel antagonist
EP1908461B1 (fr) Utilisation de l&#39;énantiomère (1S, 2R) du milnacipran pour la préparation d&#39;un médicament
Tungsubutra et al. Acute coronary syndrome in young adults: the Thai ACS Registry
JPH10512240A (ja) デスカルボエトキシロラタジンを用いるアレルギー性鼻炎および他の疾患の治療のための方法および組成物
JP2008189685A (ja) 頻尿および尿失禁の予防・治療剤
JP2005505545A (ja) 高血圧及び心不全を減少させる方法
HUE027399T2 (en) Angiotensin II Receptor Antagonist For Treatment Of Cardiovascular Disease In Cats
Yang et al. Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries
Schoeffter et al. Modulatory role of the vascular endothelium in the contractility of human isolated internal mammary artery
CN1073418C (zh) 白细胞介素－8生成抑制剂
CN1234367C (zh) 用于压迫性尿失禁治疗的芳基偶氮－取代的咪唑
Dussaillant et al. Regression of left ventricular hypertrophy in experimental renovascular hypertension: diastolic dysfunction depends more on myocardial collagen than it does on myocardial mass
Weinstein et al. Differences in alpha-adrenergic responsiveness between human internal mammary arteries and saphenous veins.
Kendall Clinical trial data on the cardioprotective effects of beta-blockade
WO1997019700A1 (en) Novel drug for relieving pain and promoting the removal of calculi in urolithiasis
AU2002311445A1 (en) Arylazo-substituted imidazole for the treatment of stress urinary incontinence
Keaton et al. Captopril treatment and its withdrawal prevents impairment of endothelium-dependent responses in the spontaneously hypertensive rat
Perez-Rivera et al. Increased reactivity of murine mesenteric veins to adrenergic agonists: functional evidence supporting increased α1-adrenoceptor reserve in veins compared with arteries
Chardigny et al. Platelets and prostacyclin in arterial bypasses: implications for coronary artery surgery
WO2001060358A1 (en) Method and compositions for treating fibrotic diseases
Schiffrin Structure and function of small arteries of essential hypertensive patients following chronic treatment with once-a-day nifedipine
JP2002527377A (ja) β３−アゴニスト活性を有する化合物の新規な治療への使用
Hu et al. New mouse model of vein bypass graft atherosclerosis
Davenport et al. The role of ureteral relaxation in the promotion of stone passage

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee